Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00024089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: gefitinib

Sponsor

National Cancer Institute (NCI)